Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Assisted Circulation”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 829 records · Page 46Linked to original sources

SWAT team approach to ventricular assistance.

In 1986, the Cardiovascular Research Institute in Sion, Switzerland, created a flying bridge-to-cardiac transplantation team. This team, consisting of two physicians, a physicist, a biomedical engineer, and two intensive care nurses, has participated in 23 bridges to cardiac transplantation in 11 cardiovascular surgery centers in Europe. The cardiac function of all patients was 100% supported by paracorporeal pneumatic biventricular Pierce-Donachy devices. Twenty of the 23 patients have had transplantation, and 11 are alive and well. The bridge-to-cardiac transplantation team, which travels with a transportable driver and the ventricle sets, supervises the bridged patients 24 hours a day until cardiac transplantation is performed.

Adolescent↗

Direct mechanical ventricular actuation: a review.

Direct mechanical ventricular actuation (DMVA) is a non-blood contacting method of circulatory support that can be rapidly instituted for resuscitation. DMVA is superior to conventional methods (open and closed-chest cardiac massage) in providing reliable cardiovascular stabilization for resuscitation following cardiac arrest. Furthermore, DMVA has important advantages including rapid application, technical simplicity, and avoidance of blood contact compared to other resuscitation devices (cardiopulmonary bypass and blood pumps). This review summarizes laboratory and clinical applications of DMVA.

Animals↗

A durable load bearing muscle to prosthetic coupling.

Skeletal muscles have been successfully linked to power mechanical support devices acutely. However, the required load bearing muscle to prosthetic interfaces have not been consistently durable. Tissue simply may not tolerate the repetitive pressure generated, ranging to 40,000 mm Hg, when necessary forces meet the crosssectional areas accessible by suture or clamp fixation. Dramatically increasing the force transfer surface by dispersing ultrafine polymer fibers in the distal muscle substance is the principle of a coupling device termed the MyoCoupler. Earlier, effective force transfer was computationally projected and confirmed in a pilot 30 day rabbit trial, with pull-out strength several times need. This investigation tested bonding strength after longer periods and examined the postulated fiber tissue integration. Devices and controls (buttressed suture fixation alone) were implanted contralaterally in the posterior tibial muscles of 28 rabbits for up to 90 days. Of the 28 rabbits, 21 were used for bond strength testing, and 3 were used for histology. Infection or procedural error disqualified 4 of the rabbits. Pull-out strength levels at 10-30 days (n = 7), 31-60 days (n = 10), 61-90 days (n=4), and all (n=21) were, respectively, 107.1 +/- 58.1, 111.4 +/- 42.7, 97.0 +/- 21.3, and 107.2 +/- 43.9 for MyoCouplers and 58.4 +/- 19.4, 52.3 +/- 34.7, 40.5 +/- 13.0, and 52.1 +/- 26.9 for the control animals. Differences were statistically significant (one-tailed t-test for paired data) and at progressively higher standards of probability for each successive period (p < 0.05 at 10-30 days, p < 0.01 at 31-60 days, p < 0.001 at 90 days, and p < 0.00001 for all). Histology showed fibrous tissue insinuation. Of 360 random fiber surface sites, 88% were closer to fibrous tissue structures than to other fibers. These findings support the aggressive pursuit of muscle powered mechanisms for artificial hearts, assist devices, and heart wall actuators.

Animals↗

Multicenter experience: prevention and management of left ventricular assist device infections.

Implantable left ventricular assist devices (LVADs) have demonstrated clinical success in both the bridge-to-transplantation and destination-therapy patient populations; however, infection remains one of the most common causes of mortality during mechanical circulatory support. Thus, serious LVAD infections may negate the benefits of LVAD implantation, resulting in decreased quality of life, increased morbidity and mortality, and increased costs associated with implantation. Prevention of device-related infection is crucial to the cost-effective use of mechanical circulatory support devices. Therefore, adherence to evidence-based infection control and prevention guidelines, meticulous surgical technique and optimal postoperative surgical site care form the foundation for LVAD associated infection prevention.

Assisted Circulation↗

Implantable ventricular assist systems.

A major goal of the Circulatory Support Program of the National Heart, Lung, and Blood Institute (NHLBI) is the development of a tether-free implantable ventricular assist system (VAS) to rehabilitate patients with advanced heart disease. In 1980, the NHLBI initiated a targeted program to develop and integrate implantable electromechanically powered VASs capable of operating for at least 2 years. The objectives of the program are to complete the development of the VAS and perform in vitro and in vivo evaluation studies. This article summarizes the research status of this NHLBI-sponsored program. It defines the VAS system requirements, describes the systems under development, identifies progress achieved to date, and identifies research challenges.

Animals↗

Current and future valves for blood pumps.

There is a variety of mechanical prosthetic valves that can be applied to blood pumps, and one can be selective about those particular characteristics tailored to each blood pump and its application. These devices have become extremely reliable, particularly since, in the experience of this laboratory, the dp/dt generated in the ventricle of the pneumatically powered artificial heart is successfully lowered. Future modifications of the valves, such as the Medtronic-Hall monostrut valve and the Medtronic-Hall tubular valve, are expected.

Animals↗

Seal-less centrifugal blood pump with magnetically suspended rotor: rot-a-flot.

Limitations of current centrifugal blood pumps are related to heat generation of bearings and leakage of seals, to dead water zones, and to poor efficiency. A new concept is proposed in this paper to ameliorate these problems based on a miniaturized magnetic drive, and a prototype is introduced. The pump rotor is suspended and driven by a radial permanent magnetic field that stabilizes the impeller in 4 of the 6 spatial degrees of freedom and allows it to be top-spun on a single blood-flushed pivot bearing with minimal load and friction. A shrouded impeller with an open center and 4 logarithmically curved channels is run inside a cone-and-plate-type housing with a spiral volute chamber. In vitro testing was performed comparing this design with the BioMedicus, St. Jude, and Sarns pumps. The prototype is demonstrated to have the smallest internal volume (35 ml), surface (190 qcm), and passage time (0.5 s at 4 L/min), as well as the highest hydraulic efficiency (up to 0.4) of all devices studied.

Assisted Circulation↗

Real-time studies of the pivot bearings in the NEDO Gyro PI-710 centrifugal blood pump.

The NEDO Gyro PI-710 centrifugal pump (Gyro PI-710 pump) incorporates a double pivot bearing system of which the male pivot and female bearings are fabricated from Al2O3 ceramic and ultrahigh molecular weight polyethylene. The top female bearing is a critical component because the impeller is levitated by hydraulic force and is maintained in the top contact position. A long-term in vitro examination of the pivot bearings was conducted using a biventricular assist model. In 7 animal experiments, the depth change of the top female bearing was examined. Animal experiments up to 90 days revealed that there was no noticeable depth increase in the top female bearing. According to the in vitro study, the life of the pivot bearings of the left and right pump was estimated to be approximately 3 and 7 years, respectively. Further improvement of this pivot bearing system is currently underway.

Assisted Circulation↗

Biochemical and functional correlates of myocardium-like transformed skeletal muscle as a power source for cardiac assist devices.

Skeletal muscles, such as the latissimus dorsi muscle, can be transformed to gain considerable fatigue resistance to be suitable either for cardiomyoplasty, or to power a cardiac assist device. Such transformation of the skeletal muscle can be achieved by low frequency electrical stimulation for several weeks. In this article, we reviewed the stimulation protocol, and subsequent histochemical, biochemical, and functional changes in the skeletal muscle, and compared them to those of the cardiac muscle. The parameters that should be useful for stimulating such a muscle to assist the heart are defined. The issues currently under study, including the optimal transformation parameters, the feasibility of working transformation, and the importance of device design to minimize vascular compromise of the muscle, are also discussed. It is concluded that there is a great potential to use the plasticity of skeletal muscle for clinical purposes, specifically by transforming the skeletal muscle to resemble the myocardium in order to use it either to replace or repair the myocardium, or as the endogenous power source for a cardiac assist device.

Animals↗

Artificial hearts.

Explore the source record for details and available documents.

Assisted Circulation↗

Mechanical support for the failing heart.

The National Heart, Lung, and Blood Institute (NHLBI) has sponsored considerable research directed toward basic studies on the etiology of heart disease and atherosclerosis. While progress has been very encouraging there are still significant numbers of patients with end-stage heart disease. NHLBI initiated goal-oriented research activities on the artificial heart based upon the recommendation of the National Heart Advisory Council in 1964. The major goal of the Artificial Heart Program was to develop devices which could be effectively used to rehabilitate patients with end-stage heart disease. This paper will describe the evolution and specific program goals of the Artificial Heart Program and provide a description of the left ventricular assist system (LVAS) and total artificial heart (TAH) research efforts. Specific attention will be directed toward defining device requirements, descriptions of the blood pump and energy converter, control system operation and energy transmission methods. A summary of experimental results and current development status will also be provided.

Assisted Circulation↗

[Utilization of aortomyoplasty as a biological pumping system].

Aortomyoplasty is a surgical technique of constructing a neo-ventricle on the ascending or descending aorta with the latissimus dorsi muscle. This is electrically stimulated to contract during diastole, thereby creating a system of chronic, haemo-compatible aortic pumping. Long-term experimental studies have shown increases in cardiac output (from 3.6 to 5.5 l/min), decreases in peripheral resistances (from 1574 to 1134 dyne.sec.cm-5) and increases in indices of subendocardial viability (DPTI/TTI: 1.1 to 1.4). These experimental studies have been confirmed by the initial clinical results. To date, world experience includes thirty-six patients. With cardiomyoplasty, aortomyoplasty is a new arm in the therapeutic arsenal against severe cardiac failure by providing a new system of chronic circulatory assistance which is implantable and biocompatible.

Aorta, Thoracic↗

[Heart assist systems with integrated microsensors (HIM 2)].

The use of intracardiac pump systems is leading to more physiological support for coronary surgery patients. But the currently available micro blood pump with an integrated micro pressure sensor and an outer diameter of 6.5 mm is not suitable for a transfemoral placement of the device. Therefore a significantly smaller pump with an outer diameter of 4 mm (12F) is been developed and tested. To transfer the sensor technology in this, for the first time the MID (moulded interconnected device) technology is applied in a medical device. In a first step MID is used to integrate a smaller pressure sensor on the existing blood pump. The result should help to find a new packaging and connecting solution for integration of the miniaturized sensor on the 4 mm pump.

Assisted Circulation↗